Drug intelligence / Profile preview

HBM7575

Development stage: Phase 1
Lead developer: Kelun-Biotech
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

HBM7575 is a bispecific antibody being developed by Harbour BioMed that targets thymic stromal lymphopoietin (TSLP) and an undisclosed second target for the treatment of inflammatory diseases. Part of the company's Type 2 Pathways program, HBM7575 is designed to simultaneously block TSLP-mediated signaling and another inflammatory pathway to provide a more comprehensive therapeutic effect than traditional monoclonal antibodies. As of early 2025, the drug is in the pre-clinical stage, with an Investigational New Drug (IND) application expected to be filed in 2025.

Other names: TSLP dual antibody

Targets

TSLP (Thymic stromal lymphopoietin)

Beyond the preview

Go deeper on HBM7575.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBM7575.

Explore the full profile